CSIMarket
 
Fibrogen Inc   (FGEN)
Other Ticker:  
 
 
Price: $2.1700 $0.08 3.828%
Day's High: $2.36 Week Perf: 14.81 %
Day's Low: $ 1.95 30 Day Perf: 0.93 %
Volume (M): 2,554 52 Wk High: $ 20.90
Volume (M$): $ 5,542 52 Wk Avg: $5.74
Open: $2.17 52 Wk Low: $0.33



 Market Capitalization (Millions $) 213
 Shares Outstanding (Millions) 98
 Employees 832
 Revenues (TTM) (Millions $) 155
 Net Income (TTM) (Millions $) -294
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 3

Fibrogen Inc
Fibrogen Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for the treatment of serious and life-threatening medical conditions. The company was founded in 1993 and is headquartered in San Francisco, California. Fibrogen's pioneering research addresses unmet medical needs in areas such as anemia, fibrosis, and cancer.

Fibrogen's flagship product is roxadustat, a first-in-class oral treatment for anemia in patients with chronic kidney disease. Roxadustat is an hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that increases endogenous erythropoietin levels and enhances iron uptake. Roxadustat is currently approved in China and Japan for the treatment of anemia caused by chronic kidney disease, and the company is pursuing regulatory approval in other markets, including Europe, the United States, and Canada.

In addition to its work on roxadustat, Fibrogen is also developing therapies for other indications. Pamrevlumab, a monoclonal antibody targeting connective tissue growth factor (CTGF), is being evaluated for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy. FG-5200, a gene therapy for cystic fibrosis, is being developed in collaboration with Astellas Pharma.

Fibrogen has an extensive research and development pipeline, with a number of programs in preclinical and clinical stages. The company has partnerships with leading pharmaceutical companies such as AstraZeneca, Astellas, and Bristol-Myers Squibb to develop and commercialize its products. Fibrogen's expertise in hypoxia-inducible factor biology and fibrosis has led to the discovery of novel targets and transformative therapies for unmet medical needs.

Fibrogen has a strong financial position, with a market capitalization of approximately $7 billion as of June 202 The company has over 4,000 employees worldwide and operates research and manufacturing facilities in the United States, China, and Sweden. Fibrogen is committed to research, development, and commercialization of treatments for debilitating and life-threatening diseases, and its innovative therapies have the potential to significantly improve the lives of patients globally.


   Company Address: 409 Illinois Street San Francisco 94158 CA
   Company Phone Number: 978-1200   Stock Exchange / Ticker: NASDAQ FGEN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Contract

FibroGen Assumes Full Control of Revolutionary Anemia Drug, Roxadustat, Except in China and South Korea; Retention of China Agreement Highlights Continued Focus on Expanding Reach in Largest CKD Market

Published Mon, Feb 26 2024 9:05 PM UTC

FibroGen, a leading biopharmaceutical company, has recently announced that it has regained all rights to its innovative therapeutic drug, Roxadustat, from AstraZeneca, with the exception of China and South Korea. The decision marks a significant development in the partnership between both companies. The FibroGen AstraZeneca China Agreement for Roxadustat will remain intact, ...

Clinical Study

FibroGen's Pamrevlumab Shows Promise in Pancreatic Cancer Clinical Program

Published Mon, Feb 5 2024 12:00 PM UTC

FibroGen, Inc. (NASDAQ: FGEN) has recently announced its plans to host Part I of a virtual KOL (Key Opinion Leader) investor event series on February 13, 2024, at 10:30 AM ET. This event aims to provide an in-depth review of the clinical program of their drug candidate, pamrevlumab, in the context of pancreatic cancer treatment.Event Details and Registration:The virtual KOL ...

Fibrogen Inc

Fibrogen Inc Witnesses Notable 155.062% Surge in Revenue Over Three-Month Fiscal Period Ending Sep 30, 2023



Fibrogen Inc, a biotech company operating in a seasonal nature of business, has recently reported some positive changes in its financial performance. However, a closer analysis reveals that these improvements might not be sustainable, leaving investors concerned about the future prospects of the company. This bearish article will delve into the recent fiscal period results of Fibrogen Inc and examine key indicators that suggest challenges ahead.
Declining Loss per Share but Concerning Net Loss:
While Fibrogen Inc managed to decrease its loss per share from $-0.98 a year ago to $-0.65 in the most recent fiscal period, the company still reported a substantial net loss of $-63.615 million. This significant financial setback indicates that the company has a long way to go to achieve profitability. Investors should be cautious, as the seemingly positive reduction in loss per share does not necessarily translate into a healthy financial position.

Fibrogen Inc

Despite Revenue Surge, Fibrogen Inc Falls Short in Q2 2023: Increased Losses Rattle Investors

Fibrogen Inc, a major player in the pharmaceutical preparations industry, has reported its financial results for the second quarter of 2023. Despite an increase in revenue of 48.692% to $44.32 million compared to the same period last year, the company's loss per share also increased to $-0.90 per share. This can be seen as a setback for Fibrogen Inc, as their peers in the industry experienced an average top-line elevation of only 2.30% from the second quarter of 2022.
In comparison to the preceding reporting period, where the company reported revenue of $36.16 million and a loss per share of $-0.81, the second quarter of 2023 saw a larger net loss of $-87.680 million, compared to $-72.624 million the previous year. This decline in profitability may be cause for concern for investors.

Fibrogen Inc

Fibrogen Inc's Financial Woes Deepen: Innovation Takes a Hit in Recent Fiscal Period

Fibrogen Inc is a pharmaceutical and biotechnology company that specializes in the development of innovative therapies for the treatment of serious and life-threatening diseases. With a focus on research and development, Fibrogen Inc has been able to bring numerous drugs to the market that have helped to improve the lives of countless patients around the world.
Despite its reputation for innovation, Fibrogen Inc has experienced some financial troubles in recent years. The most recent fiscal period, for example, saw a significant increase in losses compared to the year prior. Specifically, Fibrogen Inc's loss per share rose from $-0.68 to $-0.81, and the company's overall net loss increased from $-63.205 million to $-76.705 million.






 

Fibrogen Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com